This innovative FTSE 250 stock has had a solid start to the year, rising 15% in just two days. Is it time I considered adding ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Novo Nordisk (NVO) ended the recent trading session at $84.62, demonstrating a -1.9% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%. At the same ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

President-elect Donald Trump has asserted that, due to national security interests, he intends to acquire Greenland and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...

The biopharma industry’s deal-a-palooza, better known as the J.P. Morgan Healthcare Conference, has kicked off in San ...

At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $86.26 which represents a slight increase of $0.62 or 0.72% from the prior close of $85.64. The stock opened at $87.22 and touched a ...